Synovial Sarcoma
Symptoms, Doctors, Treatments, Advances & More

Synovial Sarcoma Overview

Save information for later
Sign Up

Learn About Synovial Sarcoma

What is the definition of Synovial Sarcoma?
Synovial sarcoma is a rare and aggressive soft tissue sarcoma. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although Synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18. This translocation is specific to Synovial sarcoma and is often used to diagnose the condition.
What are the alternative names for Synovial Sarcoma?
  • Synovial sarcoma
  • Synovial cell sarcoma
  • Synovialosarcoma
Who are the top Synovial Sarcoma Local Doctors?
Elite in Synovial Sarcoma
Elite in Synovial Sarcoma
Referral may be required

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
646-583-3648
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandra D'angelo is an Oncologist practicing medicine in New York, New York. Dr. D'angelo is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.

Elite in Synovial Sarcoma
Elite in Synovial Sarcoma
Referral may be required

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
929-379-4794
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Dickson is an Oncologist practicing medicine in New York, New York. Dr. Dickson is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, and Endoscopy. Dr. Dickson is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Synovial Sarcoma
Elite in Synovial Sarcoma
Referral may be required

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
929-459-8452
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mrinal Gounder is an Oncologist practicing medicine in New York, New York. Dr. Gounder is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Desmoid Tumor, Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Liposarcoma, and Liver Embolization. Dr. Gounder is currently accepting new patients.

View All Doctors
What are the latest Synovial Sarcoma Clinical Trials?
A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Procedure
Study Phase: Phase 1

Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called a...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1, Dose-Escalation, Open-Label Study, Evaluating the Safety and Tolerability of ZI-MA4-1, a TCR-NK Cell Therapy, in HLA-A*02:01 Positive Patients With Inoperable, Locally Advanced, or Metastatic MAGE-A4 Expressing Solid Malignancies
A Phase 1, Dose-Escalation, Open-Label Study, Evaluating the Safety and Tolerability of ZI-MA4-1, a TCR-NK Cell Therapy, in HLA-A*02:01 Positive Patients With Inoperable, Locally Advanced, or Metastatic MAGE-A4 Expressing Solid Malignancies
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Biological, Drug
Study Phase: Phase 1

Summary: This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours. Currently, these patients have a poor prognosis and a relatively short overall survival. There is a lack of meaningful, effective therapies available that improve the out...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center